We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

92 hedge funds and large institutions have $134M invested in Calithera Biosciences, Inc in 2019 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 36 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

575% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 4

174% more call options, than puts

Call options by funds: $444K | Put options by funds: $162K

125% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 16

30% more funds holding

Funds holding: 7192 (+21)

11% less capital invested

Capital invested by funds: $150M → $134M (-$16M)

Holders
92
Holders Change
+21
Holders Change %
+29.58%
% of All Funds
2%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
27
Increased
36
Reduced
16
Closed
4
Calls
$444K
Puts
$162K
Net Calls
+$282K
Net Calls Change
-$1.1M
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$26.3M +$21.2M +186,350 +123%
Federated Hermes
2
Federated Hermes
Pennsylvania
$21.4M +$9.75M +85,865 +46%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$13.8M -$608K -5,361 -3%
BlackRock
4
BlackRock
New York
$12.6M +$997K +8,781 +6%
Vanguard Group
5
Vanguard Group
Pennsylvania
$8.24M +$2.93M +25,798 +32%
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$7.55M +$11M +96,790 New
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$5.71M +$265K +2,339 +3%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$4.68M +$2.84M +25,000 +71%
CH
9
CVI Holdings
Delaware
$3.29M +$4.79M +42,162 New
Renaissance Technologies
10
Renaissance Technologies
New York
$2.93M +$1.48M +13,000 +53%
State Street
11
State Street
Massachusetts
$2.61M +$722K +6,361 +23%
SI
12
Sofinnova Investments
California
$2.07M +$3.01M +26,492 New
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$1.92M +$2.79M +24,564 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.84M +$358K +3,156 +15%
N
15
Nuveen
North Carolina
$1.74M +$2.54M +22,341 New
Northern Trust
16
Northern Trust
Illinois
$1.55M +$153K +1,346 +7%
Man Group
17
Man Group
United Kingdom
$1.43M +$70.9K +625 +4%
MIM
18
Monashee Investment Management
Massachusetts
$1.17M +$1.7M +15,000 New
Citadel Advisors
19
Citadel Advisors
Florida
$837K +$1M +8,823 +464%
CS
20
Candriam SCA
Luxembourg
$699K
Goldman Sachs
21
Goldman Sachs
New York
$695K +$247K +2,173 +32%
Assenagon Asset Management
22
Assenagon Asset Management
Luxembourg
$633K +$922K +8,120 New
BCM
23
Bridgeway Capital Management
Texas
$593K +$142K +1,250 +20%
OAM
24
Oxford Asset Management
United Kingdom
$568K -$474K -4,176 -36%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$531K +$42.4K +374 +6%

CALA Hedge Fund Activity: Q2 2019 in Review

92 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q2 2019, worth a combined $134M — down 11% from $150M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CALA positions and 4 closed out — a net gain of 23 holders — while 36 added to existing stakes and 16 trimmed.

The largest buyer was BVF Inc, adding an estimated $21.2M. The largest seller was ALPS Advisors, exiting entirely with an estimated $621K sold.

  • 92 institutional investors held Calithera Biosciences, Inc (CALA) as of Q2 2019, up from 71 in Q1 2019.
  • Funds reported $134M of Calithera Biosciences, Inc stock for Q2 2019, down 11% quarter-over-quarter.
  • 27 funds opened new Calithera Biosciences, Inc positions in Q2 2019 and 4 closed out, a net change of +23 holders.
  • The largest Calithera Biosciences, Inc buyer in Q2 2019 was BVF Inc, an estimated $21.2M added.
  • The largest Calithera Biosciences, Inc seller in Q2 2019 was ALPS Advisors, an estimated $621K sold.

Based on aggregated 13F filings for Q2 2019.